Tralokinumab demonstrates real-world utility for atopic dermatitis

Key takeaways:

• Researchers compiled findings from seven studies demonstrating the real-world utility of tralokinumab for atopic dermatitis.
• Across the trials, as high as 64.6% of patients reached IGA 0 or 1 within 16 weeks.

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of tralokinumab for the treatment of atopic dermatitis.

“Tralokinumab is a novel IgG4 monoclonal antibody against interleukin-13 recently approved for moderate to severe AD in adults and adolescents,” Siddhartha Sood, HBSc, of Temerty Faculty of Medicine at the University of Toronto, and colleagues wrote. “While its efficacy and safety have been demonstrated in clinical trials, real-world data remain limited.”

In this research letter, Sood and colleagues offered evidence from various studies supporting tralokinumab’s use in routine clinical practice.

Retrospective trial

The authors conducted a retrospective multicenter study comprised of 48 adults and adolescents (mean age, 48.5 years; age range, 14-82 years; 56.3% male) with AD who were treated with a 600 mg loading dose of tralokinumab followed by 300 mg every other week.

Results showed that 64.6% of patients reached an IGA score of clear or almost clear by week 16 ± 8. Similarly, 50% reached EASI 90 and 22.9% achieved EASI 100.

According to the DLQI, 35.4% of patients reported a score of 0 or 1 by week 16 ± 8.

Of the 14 patients that were on previous biologic treatments including dupilumab, abrocitinib and upadacitinib, 42.9%, 28.6% and 28.6% achieved IGA 0 or 1, EASI 75 and EASI 90.

Treatment-emergent adverse events were reported in six patients and included headache (n = 2), generalized urticaria (n = 1) and conjunctivitis (n = 3). Six discontinuations occurred due to treatment-related adverse events (n = 4) and lack of efficacy (n = 2).

ECZTRA trials

The ECZTRA program was comprised of multiple double-blind, placebo-controlled, phase 3 trials, four of which are reported in this research letter: ECZTRA1 (n = 603), ECZTRA2 (n = 593), ECZTRA3 (n = 380) and ECZTRA7 (n = 277).

Across the trials, 15.8% to 38.9% of tralokinumab-treated patients reached an IGA score of 0 or 1. Additionally, 25% to 64.2% and 14.5% to 41.1% achieved EASI 75 and EASI 90, respectively, by week 16.

Worldwide trials

The authors found other studies around the globe that also support the efficacy of tralokinumab, including a Spanish study (n = 85) where 19%, 58% and 21% of tralokinumab-treated patients reached IGA 0 or 1, EASI 75 and EASI 90, respectively, by week 16.

A Japanese study (n = 103) also exemplified high response rates among tralokinumab-treated patients with 14%, 38.3% and 23.4% achieving IGA 0 or 1, EASI 75 and EASI 90, respectively, by week 12.

Conclusion

The authors report that their retrospective study confirms the similar findings of these other trials, showcasing the ability of tralokinumab to inspire superior response rates across efficacy endpoints while maintaining a consistent safety profile.

“Overall, we demonstrate the real-world utility of tralokinumab for AD,” the authors concluded.